Anna Vila Soriano

Mrs. Anna Vila Soriano


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Animals
Verified
Journal Article
Open access
PDF file
LGLaura Gil
Laura Gil
GMGermán Martín
Germán Martín
CSCarme Soler
Carme Soler
ASAnna Vila Soriano
Anna Vila Soriano
RSRocío Saiz-Álvarez
Rocío Saiz-Álvarez
PNPaula Fátima Navarro
Paula Fátima Navarro
The use of omeprazole as a preventive treatment for gastrointestinal ulcers in veterinary medicine has been questioned during previous years. The aim of the present study is to assess the long-term effect of omeprazole on cobalamin and serum gastrin levels in healthy dogs. Eighteen healthy dogs were included: 10 in the control group and 8 in the omeprazole group. Three samples were collected: before starting the treatment (T0), 30 days after the start of treatment (T1), and at 60 days (T2). The mean cobalamin value (ng/L) in the control group was 481.4 (±293.70) at T0, 481.4 (±170.21) at T1, and 513.2 (±174.50) at T2. In the omeprazole group, the values were 424.62 (±161.57) at T0, 454.5 (±160.96) at T1, and 414.87 (±127.90) at T2. No statistically significant changes were detected in cobalamin levels between the three-time period in both study groups. These results agree with previous findings in felines but contrast with human medicine studies. The median gastrin values (pg/mL) in the control group were 62.45 [30.17–218.75] at T0, 76.06 [30.67–199.87] at T1, and 63.02 [35.81–176.06] at T2. The median gastrin value in the omeprazole group was 67.59 [55.96–101.60] at T0, 191.77 [75.31–1901.77] at T1, and 128.16 [43.62–1066.46] at T2. Statistically significant differences were detected (p = 0.008), indicating an increase in gastrin levels after initiating treatment with omeprazole. In conclusion, the increased levels of gastrin observed in this population underscore the importance of conducting a comprehensive clinical assessment to identify potential gastrointestinal disorders, particularly in consideration of the usage of omeprazole as a preventive treatment.